Exhibitors Search
FORTUNA HELIX

Booth no.
A60/H60
Exhibition | PARTNERING |
---|---|
Country | Korea, South |
Address | 117-3 Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea |
Tel (Rep.) | 02-6216-0617 |
Website | http://www.fortunahelix.com |
Company Introduction
Fortuna Helix applies advanced genomic analysis to predict disease risk and inform preventive healthcare. By examining more than 3.9 million genetic markers, we provide individualized risk assessments for 37 major diseases, spanning cancer, cardiovascular and metabolic disorders, neurological conditions, autoimmune diseases, mental health, gastrointestinal and liver disorders, and other chronic conditions. Our programs also extend beyond disease risk, including Obesity Prediction, General Health Indicators, and Height Prediction. Using polygenic risk scores (PRS) and validated models, we help individuals understand their susceptibility to conditions like obesity, where early insight enables proactive management and reduced downstream health risks. Our General Health Indicators program offers a broader picture of physical, physiological, biochemical, and cognitive health, turning complex genomic information into a clear, accessible roadmap for long-term wellness.
Promotional video
Exhibit Item
Cloud-Based Genomic Analysis Solution for Identifying High-Risk Disease Groups: Disease Prediction, Disease Prevention, Obesity Prediction, Height Prediction, Genetic Health Indicators
Exhibit Item Images
-
Product Name : Cloud-Based Genomic Analysis Solution for Identifying High-Risk Disease GroupsCloud-Based Genomic Analysis Solution for Identifying High-Risk Disease Groups Fortuna Helix offers three key programs: Disease Prediction, assessing risk for 37 major conditions using genomic analysis; Obesity Prediction, applying PRS to identify susceptibility and support early prevention; and General Health Indicators, providing a holistic view
Exhibit Description
Fortuna Helix offers three key programs: Disease Prediction, assessing risk for 37 major conditions using genomic analysis; Obesity Prediction, applying PRS to identify susceptibility and support early prevention; and General Health Indicators, providing a holistic view of physical, biochemical, and cognitive health.
Co-Exhibitor or
Partner’s Information
Company Name | Country |
---|---|